The new generation of hep C drugs has completely changed the conversation about launches.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
Just like 2016 and the year before, specialty drugs dominate the 2017 list of top performers in the most recent first year after launch class.
First Year After Launch: New molecular entities launched in the U.S. during 2015 that generated 2016 sales of at least $200 million
A listing of the the new molecular entities launched in the United States during 2015 that generated 2016 sales of at least $200 million
Lurking behind all the sound and fury in the political realm, 2017 is bringing new opportunities to marketers that have nothing at all to do with orange hair. A whole generation of technologies are growing to maturity together – predictive targeting, virtual reality, behavioral science, interactive video, big data, and more – all of which are transforming the ways in which brands can communicate with their audiences. But of course politics will matter too in this Year One of the Trump administration, as the continuing debate over drug pricing and the impact of the new president’s policies on the pharma industry remain very much up in the ai
There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.
“Failing to plan is planning to fail” states time management guru Alan Lakein. Nowhere does this axiom ring more true than in the tightly controlled world of Rx launches. Given the time and expense required to bring a prescription drug to market, coupled with its limited exclusive lifespan, we must maximize every moment from market conditioning to loss of exclusivity (LOE).
A ruling by the Delaware District Court in the United States upheld the validity of UCB’s patent for the epilepsy drug Vimpat.
Long term use of AstraZeneca’s blood thinner Brilinta has been recommended as a cost-effective option in the UK for treating patients after a heart attack.
Bristol-Myers Squibb reported disappointing 2Q 2016 sales of its Yervoy melanoma treatment.
J&J raised its full-year 2016 sales and earnings forecasts and reported quarterly results that beat estimates, helped by strength in its Rx drugs business.
Healthcare spending in the United States will likely grow by an average 5.8 percent per year over the next decade according to updated projections from the federal government.
Investors in AbbVie are getting a bit antsy as that company’s blockbuster rheumatoid arthritis drug Humira loses its patent protection later this year.
World Health Organization advisers have recommended using a fifth of the standard dose of yellow fever vaccine in the event of a global shortage to combat the worst outbreak of the deadly disease in decades.
Four U.S. senators introduced a bill aimed at preventing big pharmaceutical companies from using safety rules to prevent generic drugs from coming to market.
The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.
IMS analysis revealed that lower-cost copies of complex biotechnology drugs could save the United States and Europe’s five top markets as much as €98 billion ($110 billion) by 2020.
Americans pay the highest prices in the world for cancer drugs, but the treatments are least affordable in lower income countries.
An HIV drug approved less than 3 years ago is to be rolled out in Botswana as a core medicine for newly diagnosed patients.
Chinese health authorities announced price cuts of up to two-thirds for three expensive drugs.
Roche’s breast cancer drug Perjeta (pertuzumab) has been turned down for use on Britain’s state health service.
India has reversed course and granted approval to Gilead Sciences’ patent for its hepatitis C drug Sovaldi.
Regeneron Pharmaceuticals, facing slowing sales of blockbuster eye drug Eylea, said it was making substantial progress in securing more insurance coverage for cholesterol drug Praluent.
France will press its G7 partners this month to launch an “irreversible” process to control the prices of new medicines, part of a global drive to make life-saving drugs more affordable.
Britain’s healthcare cost watchdog NICE said on Friday it had changed its mind and decided to recommend Sanofi’s prostate cancer drug Jevtana after the French company agreed to a further discount. The National Institute for Health and Care Excellence (NICE) said the improved discount was “an excellent example of how pharma companies can work […]
New heart drugs hailed as breakthrough treatments by researchers are struggling to gain traction among prescribing doctors, posing a headache for makers such as Novartis, which reported more weak sales for its Entresto medicine.